United Therapeutics Corporation (UTHR)

Several events impacted UTHR's stock price in the past six months. Positive results from the TETON-1 study of nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) caused the stock to surge. A new $2 billion stock repurchase program led to an increase in the stock price. Positive Phase 3 results for ralinepag in pulmonary arterial hypertension (PAH) contributed to investor optimism and a stock surge. Q4 2025 earnings per share (EPS) beat analyst estimates, but revenue missed expectations, causing the stock to trade down. Initial positive results for the TETON-2 study of Tyvaso in IPF led to a stock gain, and the full results were published in March 2026. Q3 2025 EPS beat estimates, but revenue fell short, with sales rising year-over-year.

Information regarding specific demand seasonality for United Therapeutics' products and services is not readily available. The company's products address chronic and life-threatening diseases, suggesting a relatively consistent demand driven by medical need rather than seasonal fluctuations. No explicit data on demand seasonality was found.

United Therapeutics Corp. is a biotechnology company focused on developing and commercializing products for patients with chronic and life-threatening diseases, particularly in pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and organ manufacturing. The company's core business revolves around its product portfolio for pulmonary hypertension, which includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Adcirca. The company also markets Unituxin for high-risk neuroblastoma and is a pioneer in organ manufacturing technologies, including xenotransplantation, 3D bioprinting of organ alternatives, and ex vivo lung perfusion services.

United Therapeutics is co-headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, with additional facilities in Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Washington, D.C. in the United States. The company also has facilities in Magog and Bromont, Quebec, Canada. While it operates internationally, the United States generates the majority of its revenue.

United Therapeutics operates as a Public Benefit Corporation, emphasizing a mission-driven strategy focused on developing life-saving therapies and expanding the availability of transplantable organs, which generally contributes positively to its brand reputation. However, ongoing patent litigation with Liquidia Technologies, Inc. and claims of anticompetitive tactics could potentially impact public perception. Significant insider selling, including by the CEO, can sometimes be viewed with caution by investors.

United Therapeutics' ownership is highly concentrated among institutional investors, including The Vanguard Group, BlackRock, Inc., and State Street Global Advisors. Approximately 72.50% of the company's stock is owned by institutional investors, 1.74% by insiders, and 25.76% by public companies and individual investors. CEO Martine Rothblatt has engaged in insider selling.